Health
Pfizer Advances Once-Daily Weight Loss Pill
Pfizer plans to advance a once-daily version of its obesity pill, danuglipron, into clinical trials in the second half of this year. This decision follows encouraging data from early-stage trials, despite previously discontinuing a twice-daily version due to patient safety concerns, including issues with liver enzymes. The new formulation aims